1 January 2024 - The January 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The January issue of the Schedule includes a few major new/revised listings:

• Acalabrutinib (Calquence) - new indication
• Adalimumab (Ardalicip) - new biosimilar medicine
• Lumacaftor with ivacaftor (Orkambi) - new indication
• Olaparib (Lynparza) - new indication
• Pembrolizumab (Keytruda) - restriction change
• Pomalidomide (Pomolide) - new strength
• Ravulizumab (Ultomiris) - new indication 
• Ustekinumab (Stelara) - new indication

Read Summary of PBS changes